血清微小RNA-210作为接受经动脉化疗栓塞的肝细胞癌患者治疗反应和预后的预测生物标志物。
Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
作者信息
Zhan Meixiao, Li Yong, Hu Baoshan, He Xu, Huang Jianwen, Zhao Yan, Fu Sirui, Lu Ligong
机构信息
Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
Department of Interventional Radiology, Cancer Center, Guangdong Provincial Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Weilun Building, Guangzhou 510080, China.
出版信息
J Vasc Interv Radiol. 2014 Aug;25(8):1279-1287.e1. doi: 10.1016/j.jvir.2014.04.013. Epub 2014 Jun 13.
PURPOSE
To investigate whether serum microRNA-210 (miR-210) level can serve as an indicator of prognosis and a predictor of efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma (HCC).
MATERIALS AND METHODS
Serum miR-210 level was measured in 113 patients with HCC before transarterial chemoembolization (t1), 3 days after transarterial chemoembolization (t2), and 4 weeks after transarterial chemoembolization (t3) and compared with 39 healthy control subjects. The correlations between miR-210 levels and clinicopathologic factors, tumor responsiveness, and prognosis were analyzed. The modified Response Evaluation Criteria in Solid Tumors assessment was conducted at t3.
RESULTS
A higher mean baseline miR-210 level was observed in patients with HCC compared with control subjects (3.69 ± 2.04 vs 1.08 ± 0.45, P < .001). A positive correlation between baseline miR-210 level and tumor size (P < .001), vascular invasion (P = .005), tumor differentiation (P = .037), and Barcelona Clinic Liver Cancer stage (P < .001) was observed. Elevated baseline miR-210 level also served as an independent prognostic factor predicting poor overall survival (risk ratio, 2.082; P = .003). Patients who did not respond to transarterial chemoembolization had higher baseline miR-210 levels than patients who did respond to treatment (4.34 ± 1.67 vs 3.28 ± 2.15, P < .001). In addition, miR-210 levels increased significantly 4 weeks after transarterial chemoembolization in nonresponders (5.79 ± 2.06 at t3 vs 4.34 ± 1.67 at t1, P < .001), whereas no significant change was observed in responders (3.53 ± 2.20 at t3 vs 3.28 ± 2.15 at t1, P = .116). Lastly, an inverse correlation was identified between miR-210 change t1-t3 with the time to radiologic progression (P < .001).
CONCLUSIONS
Serum miR-210 may represent a novel biomarker for predicting efficacy of transarterial chemoembolization and overall survival for patients with HCC.
目的
探讨血清微小RNA-210（miR-210）水平是否可作为肝细胞癌（HCC）患者经动脉化疗栓塞术预后的指标及疗效预测指标。
材料与方法
检测113例HCC患者经动脉化疗栓塞术前（t1）、术后3天（t2）及术后4周（t3）的血清miR-210水平，并与39例健康对照者进行比较。分析miR-210水平与临床病理因素、肿瘤反应性及预后的相关性。在t3时进行实体瘤改良疗效评价标准评估。
结果
与对照组相比，HCC患者的平均基线miR-210水平更高（3.69±2.04 vs 1.08±0.45，P<.001）。观察到基线miR-210水平与肿瘤大小（P<.001）、血管侵犯（P=.005）、肿瘤分化（P=.037）及巴塞罗那临床肝癌分期（P<.001）呈正相关。基线miR-210水平升高也是预测总体生存不良的独立预后因素（风险比，2.082；P=.003）。对经动脉化疗栓塞术无反应的患者基线miR-210水平高于有反应的患者（4.34±1.67 vs 3.28±2.15，P<.001）。此外，无反应者经动脉化疗栓塞术后4周miR-210水平显著升高（t3时为5.79±2.06，t1时为4.34±1.67，P<.001），而有反应者未观察到显著变化（t3时为3.53±2.20，t1时为3.28±2.15，P=.116）。最后，确定miR-210 t1至t3的变化与放射学进展时间呈负相关（P<.001）。
结论
血清miR-210可能是预测HCC患者经动脉化疗栓塞术疗效及总体生存的新型生物标志物。
Zotero 插件